Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 18:26:46 +0200Wed, 29 May 2024 14:17:00 +0200Human medicines European public assessment report (EPAR): Hemlibra, emicizumab, Date of authorisation: 23/02/2018, Revision: 18, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/hemlibraHuman medicines European public assessment report (EPAR): Hemlibra, emicizumab, Date of authorisation: 23/02/2018, Revision: 18, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/hemlibraWed, 29 May 2024 14:17:00 +0200Human medicineHemlibra : EPAR - Procedural steps taken and scientific information after authorisationhttps://www.ema.europa.eu/system/files/documents/procedural-steps-after/h-4406-steps-after_en_1.pdfHemlibra : EPAR - Procedural steps taken and scientific information after authorisationhttps://www.ema.europa.eu/system/files/documents/procedural-steps-after/h-4406-steps-after_en_1.pdfWed, 29 May 2024 14:15:00 +0200Human medicine